PURPOSE: The combination of DNA methylation inhibitors and histone deacetylase inhibitors is synergistic in gene expression activation and may overcome platinum resistance. Sequential treatment with azacitidine and valproic acid (VPA) in combination with carboplatin may overcome resistance to platinum-based therapy, and we conducted a phase I trial to assess safety, maximum tolerated dose (MTD), and clinical correlates. Experimental Design Patients with advanced solid tumors refractory to standard therapy were eligible. In cohorts of escalating doses, patients received azacitidine for 5 days from days 1 to 5, VPA for 7 days from days 5 to 11, and carboplatin starting in the second cycle on days 3 and 10. Clinical correlates included evaluation of epigenetic changes, methylation patterns, and histone acetylation levels in peripheral blood mononuclear cells. RESULTS: Thirty-two patients were treated. The MTD was 75 mg/m(2) azacitidine, 20 mg/kg VPA, and AUC 3.0 carboplatin. Minor responses or stable disease lasting ≥ 4 months were achieved by six patients (18.8 %), including three with platinum-resistant or platinum-refractory ovarian cancer. The most common adverse events grade ≥ 3 were fatigue (81 %) and neutropenia (69 %). Dose-limiting toxicity occurred in six patients (18.8 %), including four patients with grade 3 altered mental status. Death receptor 4 (DR4) methylation was shown to decrease in a subset of patients, but there was no relationship with tumor response or number of cycles received. CONCLUSIONS: Combination of azacitidine, VPA, and carboplatin demonstrates decreased DR4 methylation and modest evidence of antitumor activity in patients with heavily treated advanced malignancies.
PURPOSE: The combination of DNA methylation inhibitors and histone deacetylase inhibitors is synergistic in gene expression activation and may overcome platinum resistance. Sequential treatment with azacitidine and valproic acid (VPA) in combination with carboplatin may overcome resistance to platinum-based therapy, and we conducted a phase I trial to assess safety, maximum tolerated dose (MTD), and clinical correlates. Experimental Design Patients with advanced solid tumors refractory to standard therapy were eligible. In cohorts of escalating doses, patients received azacitidine for 5 days from days 1 to 5, VPA for 7 days from days 5 to 11, and carboplatin starting in the second cycle on days 3 and 10. Clinical correlates included evaluation of epigenetic changes, methylation patterns, and histone acetylation levels in peripheral blood mononuclear cells. RESULTS: Thirty-two patients were treated. The MTD was 75 mg/m(2) azacitidine, 20 mg/kg VPA, and AUC 3.0 carboplatin. Minor responses or stable disease lasting ≥ 4 months were achieved by six patients (18.8 %), including three with platinum-resistant or platinum-refractory ovarian cancer. The most common adverse events grade ≥ 3 were fatigue (81 %) and neutropenia (69 %). Dose-limiting toxicity occurred in six patients (18.8 %), including four patients with grade 3 altered mental status. Death receptor 4 (DR4) methylation was shown to decrease in a subset of patients, but there was no relationship with tumor response or number of cycles received. CONCLUSIONS: Combination of azacitidine, VPA, and carboplatin demonstrates decreased DR4 methylation and modest evidence of antitumor activity in patients with heavily treated advanced malignancies.
Authors: Hiromu Suzuki; Edward Gabrielson; Wei Chen; Ramaswamy Anbazhagan; Manon van Engeland; Matty P Weijenberg; James G Herman; Stephen B Baylin Journal: Nat Genet Date: 2002-05-06 Impact factor: 38.330
Authors: J F Costello; M C Frühwald; D J Smiraglia; L J Rush; G P Robertson; X Gao; F A Wright; J D Feramisco; P Peltomäki; J C Lang; D E Schuller; L Yu; C D Bloomfield; M A Caligiuri; A Yates; R Nishikawa; H Su Huang; N J Petrelli; X Zhang; M S O'Dorisio; W A Held; W K Cavenee; C Plass Journal: Nat Genet Date: 2000-02 Impact factor: 38.330
Authors: Siqing Fu; Wei Hu; Revathy Iyer; John J Kavanagh; Robert L Coleman; Charles F Levenback; Anil K Sood; Judith K Wolf; David M Gershenson; Maurie Markman; Bryan T Hennessy; Razelle Kurzrock; Robert C Bast Journal: Cancer Date: 2010-11-08 Impact factor: 6.860
Authors: Kurtis E Bachman; Ben Ho Park; Ina Rhee; Harith Rajagopalan; James G Herman; Stephen B Baylin; Kenneth W Kinzler; Bert Vogelstein Journal: Cancer Cell Date: 2003-01 Impact factor: 31.743
Authors: Toshiyasu Taniguchi; Marc Tischkowitz; Najim Ameziane; Shirley V Hodgson; Christopher G Mathew; Hans Joenje; Samuel C Mok; Alan D D'Andrea Journal: Nat Med Date: 2003-04-07 Impact factor: 53.440
Authors: Andy Trotti; A Dimitrios Colevas; Ann Setser; Valerie Rusch; David Jaques; Volker Budach; Corey Langer; Barbara Murphy; Richard Cumberlin; C Norman Coleman; Philip Rubin Journal: Semin Radiat Oncol Date: 2003-07 Impact factor: 5.934
Authors: Christopher R Getchell; Eric T McCarthy; Douglass W Tucker; Anders W Ohman; Naoko Sasamoto; Shuyun Xu; Joo Yeon Ko; Mamta Gupta; Amy Shafrir; Jamie E Medina; Jonathan J Lee; Lauren A MacDonald; Ammara Malik; Kathleen T Hasselblatt; Wenjing Li; Hong Zhang; Samuel J Kaplan; George F Murphy; Michelle S Hirsch; Joyce F Liu; Ursula A Matulonis; Kathryn L Terry; Christine G Lian; Daniela M Dinulescu Journal: Clin Cancer Res Date: 2017-12-20 Impact factor: 12.531
Authors: Robert Brown; Edward Curry; Luca Magnani; Charlotte S Wilhelm-Benartzi; Jane Borley Journal: Nat Rev Cancer Date: 2014-09-25 Impact factor: 60.716
Authors: Janneke F Linnekamp; Raju Kandimalla; Evelyn Fessler; Joan H de Jong; Hans M Rodermond; Gregor G W van Bochove; Frans O The; Cornelis J A Punt; Willem A Bemelman; Anthony W H van de Ven; Pieter J Tanis; Elles M Kemper; Lianne Koens; Evelien Dekker; Louis Vermeulen; Hanneke W M van Laarhoven; Jan Paul Medema Journal: Cancers (Basel) Date: 2021-05-13 Impact factor: 6.639